| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
CKD-516 manufacturers
- Valecobulin
-
- $297.00
-
2026-05-11
- CAS:1188371-47-2
- Purity:
- Supply Ability: 10g
- Valecobulin
-
- $297.00
-
2025-07-21
- CAS:1188371-47-2
- Purity:
- Supply Ability: 10g
|
| | CKD-516 Basic information |
| Product Name: | CKD-516 | | Synonyms: | CKD-516;(2S)-2-amino-3-methyl-N-[4-[3-(1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl]-1,3-thiazol-2-yl]butanamide;Butanamide, 2-amino-3-methyl-N-[4-[3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl]-2-thiazolyl]-, (2S)-;Valecobulin | | CAS: | 1188371-47-2 | | MF: | C26H28N6O5S | | MW: | 536.6 | | EINECS: | | | Product Categories: | | | Mol File: | 1188371-47-2.mol |  |
| | CKD-516 Chemical Properties |
| density | 1.38±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 125 mg/mL (232.95 mM) | | pka | 6.43±0.50(Predicted) | | form | Solid | | color | White to off-white |
| | CKD-516 Usage And Synthesis |
| Uses | Valecobulin (CKD516) is a valine proagent of (S516) and a vascular disrupting agent (VDA). Valecobulin is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors[1][2]. | | in vivo | Valecobulin (5 mg/kg; intraperitoneal injection; administered on days 2, 6, 10, and 14; male BALB/C nu/nu mice) treatment shows markedly antitumor efficacy in various human tumor xenograft models[1]. | Animal Model: | Male BALB/C nu/nu mice (5-6 weeks of age) with HCT-116 or HCT-15 cells[1] | | Dosage: | 5 mg/kg | | Administration: | Intraperitoneal injection; administered on days 2, 6, 10, and 14 | | Result: | Had shown marked antitumor efficacy in various human tumor xenograft models.
|
| | References | [1] Lee J, et al. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. J Med Chem. 2010 Sep 9;53(17):6337-54. DOI:10.1021/jm1002414
[2] Joo I, et al. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors. Radiology. 2014 Aug;272(2):417-26. DOI:10.1148/radiol.14131165 |
| | CKD-516 Preparation Products And Raw materials |
|